GT Biopharma Reports Director/Officer Changes and Compensation
Ticker: GTBP · Form: 8-K · Filed: Jun 7, 2024 · CIK: 109657
Sentiment: neutral
Topics: management-change, officer-appointment, director-election, compensation
TL;DR
GT Biopharma filed an 8-K detailing director/officer changes and compensation arrangements.
AI Summary
GT Biopharma, Inc. filed an 8-K on June 7, 2024, reporting on events that occurred on June 3, 2024. The filing primarily concerns the departure of directors or certain officers, the election of directors, the appointment of certain officers, and compensatory arrangements for certain officers. Specific details regarding the individuals involved, their roles, and the nature of the compensatory arrangements are not provided in this excerpt.
Why It Matters
Changes in a company's board of directors and executive officers, along with details on their compensation, can signal shifts in strategy or governance that may impact future performance.
Risk Assessment
Risk Level: medium — Changes in key personnel and compensation structures can indicate internal shifts that may affect the company's future direction and performance.
Key Players & Entities
- GT Biopharma, Inc. (company) — Registrant
- June 3, 2024 (date) — Date of earliest event reported
- June 7, 2024 (date) — Date of report filing
- Delaware (jurisdiction) — State of incorporation
FAQ
What specific changes occurred regarding GT Biopharma's directors or officers?
The filing indicates a reportable event concerning the departure of directors or certain officers, the election of directors, and the appointment of certain officers.
What is the date of the reportable event for this 8-K filing?
The earliest event reported occurred on June 3, 2024.
When was this 8-K filing submitted to the SEC?
This 8-K filing was submitted on June 7, 2024.
What are the primary items covered in this 8-K filing?
The filing covers the departure of directors or certain officers, election of directors, appointment of certain officers, and compensatory arrangements of certain officers.
What is GT Biopharma, Inc.'s state of incorporation?
GT Biopharma, Inc. is incorporated in Delaware.
Filing Stats: 1,081 words · 4 min read · ~4 pages · Grade level 10.9 · Accepted 2024-06-07 17:25:06
Key Financial Figures
- $0.001 — nge on which registered Common stock, $0.001 par value GTBP The Nasdaq Stock Mar
- $375,000 — n will receive an annual base salary of $375,000 and is eligible to earn an annual discr
Filing Documents
- form8-k.htm (8-K) — 44KB
- ex10-1.htm (EX-10.1) — 54KB
- 0001493152-24-023195.txt ( ) — 281KB
- gtbp-20240603.xsd (EX-101.SCH) — 3KB
- gtbp-20240603_lab.xml (EX-101.LAB) — 33KB
- gtbp-20240603_pre.xml (EX-101.PRE) — 22KB
- form8-k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. GT BIOPHARMA, INC. Date: June 7, 2024 By: /s/ Alan Urban Alan Urban Chief Financial Officer